Drug induced liver injury (DILI) is a common cause of jaundice (2-10 %) in hospitalized settings. Diagnosing DILI clinically is a dogmatic task as DILI can mimic almost any cause of acute or chronic hepatitis. Lack of specific clinical, biochemical or imaging findings and concomitant systemic illness makes DILI a diagnosis of exclusion, recognition of which is extremely important to prevent long term hepatic injury.
Drug induced liver injury (DILI) is a common cause of jaundice (2-10 %) in hospitalized settings. Diagnosing DILI clinically is a dogmatic task as DILI can mimic almost any cause of acute or chronic hepatitis. Lack of specific clinical, biochemical or imaging findings and concomitant systemic illness makes DILI a diagnosis of exclusion, recognition of which is extremely important to prevent long term hepatic injury. [1] We report a 54 yearsold non-alcoholic man who initially presented to our hematology clinic with complaints of backache of 3 months duration. Investigations revealed anemia (Hb: 8 g/dl), renal failure (Creatinine: 3.2 mg/dl), hypercalcemia (calcium: 12.4 mg/dl), sedimentation rate of 98 mm/ h and punched out Lytic lesions in skull, pelvis and vertebrae. Bone marrow aspirate revealed 32 % plasma cells. Serum protein electrophoresis (SPEP) with immune-fixation identified monoclonal (M) band (4.2 g/l, IgG Kappa), thereby confirming a diagnosis of Multiple myeloma ISS-II (b2 microglobulin-4 mg/dl). Urine electrophoresis and Bence jones proteins were negative. Liver function tests (LFT) and viral serologies for hepatitis B, hepatitis C and HIV were normal. Hypercalcemia and renal dysfunction were managed with saline hydration and bisphosphonates followed by a combination of oral Cyclophosphamide (300 mg/m 2 ) and dexamethasone (40 mg) administered weekly and bortezomib (1.3 mg/m 2 ) on day 1, 4, 8 and 11 in a 4 weekly schedule (CyBorD). Cotrimoxazole and Acyclovir were used as prophylaxis for Pneumocystis jeroveci and herpes zoster respectively. Serum calcium and Creatinine levels normalized following the first cycle. Patient presented currently with jaundice and pruritus 2 days after receiving second dose of bortezomib during second cycle of CyBorD. He denied any fever, abdominal pain and herbal drug intake. Patient was conscious, oriented to time, place and person with blood pressure-120/ 72 mm hg, pulse rate-72/min. General examination revealed marked icterus without any features of hepatic encephalopathy. Abdomen examination revealed hepatomegaly (4 cm) in the absence of free fluid or splenomegaly. Rest of the systemic examination was unremarkable. Laboratory investigations revealed Hb-8.8 g/dL, white cell counts-570 9 10 9 /l, differential counts-68 % polymorphs, 22 % lymphocytes, 8 % monocytes and 2 % eosinophils, platelets-533 9 10 9 /l, sedimentation rate-45 mm/hour, total bilirubin-15.50 mg/dl, direct fraction-12. (Figs. 1, 2 ). There was no evidence of plasma cell infiltration or amyloid deposition in the liver. Considering a possibility of DILI, Cyclophosphamide and bortezomib were stopped and patient was started on thalidomide based regimen (Thalidomide 100 mg daily and dexamethasone 40 mg weekly). Conservative management with ursodeoxycholic acid led to normalisation of LFTs gradually over 4 weeks. After normalization of the LFTs, Cyclophosphamide was reintroduced in the treatment (300 mg/m 2 weekly) along with thalidomide (100 mg daily), dexamethasone (40 mg weekly) [CTD regimen], Cotrimoxazole and Acyclovir. Reintroduction of Cyclophosphamide, Cotrimoxazole and acyclovir was well tolerated without any recurrence of hepatitis and therefore, bortezomib was implicated as a culprit agent in severe cholestasis. Patient achieved CR after two cycles of CTD and was planned for autologous stem cell transplantation. Although at autopsy 45 % cases show plasma cell infiltration in the liver, clinical liver involvement in multiple myeloma is unusual [2] . Liver involvement in myeloma can take multiple forms including extramedullary plasmacytoma (space occupying lesion), light chain deposition, amyloidosis or diffuse plasma cell infiltration. Clinical manifestations vary from asymptomatic elevation of ALP with normal or slightly elevated aminotransferase levels to liver failure secondary to massive plasma cell or amyloid infiltration [2, 3] . Treatment of myeloma is plagued by DILI as vinca alkaloids and anthracyclins are hepatotoxic and thalidomide may also be hepatotoxic. Steroids and bortezomib were considered hepato-safe in myeloma till recently when concerns were raised regarding bortezomib induced hepatotoxicity. [2, 4] Thrombocytopenia, peripheral neuropathy and gastrointestinal side effects are the most commonly reported adverse events with bortezomib [5] . Since its first recognition in 2005 by Rosinol et al. [6] , few cases of bortezomib induced hepatitis have been described thereafter. Kim et al. [5] reported a 52-years old myeloma patient who developed severe hepatitis 3 days after the second dose of bortezomib characterized by normal bilirubin and an elevated aminotransferase levels (out of proportion to ALP) which settled in 2 weeks of stopping bortezomib. Bortezomib induced liver changes includes pigment deposition in hepatocytes, vacuolization and hepatocellular hypertrophy [5] . Chalasani et al. [7] recently proposed an algorithm for the diagnosis and management of DILI according to 'R' value (ALT/ALT ULN7ALP/ALP ULN, where R \ 2, 2-5 and [5 indicates cholestasis, mixed and hepatocellular pattern respectively). Our patient developed a cholestatic pattern of injury (R value-0.46) during second cycle of bortezomib therapy which resolved gradually over 4 weeks of stopping bortezomib. This is in contrast to previously reported hepatocellular pattern seen with bortezomib. Since, reintroduction of Cyclophosphamide, Cotrimoxazole and Acyclovir in the treatment was well tolerated without any recurrence of hepatic derangement, bortezomib was the likely culprit in our case and hence, rechallenge with this novel agent was not attempted. Attainment of CR with thalidomide based regimen strengthens the fact that there is no cross-hepatotoxicity between proteasome inhibitors and immunomodulators (thalidomide). Current case describes a previously unreported cholestatic pattern of injury with bortezomib and highlights the fact that even delayed hepatotoxicity may be seen with the use of this novel agent, obligating periodic monitoring of LFT during its use.
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